Clinical and real-world evidence have demonstrated the potential of GLP-1RAs to reduce the risk of all-cause dementia and dementia due to AD in people with T2D [32, 34,35,36], and liraglutide has been shown to reduce neurodegeneration and the speed of decline in cognitive function in people with AD [29, 30]
The American Journal of Clinical Nutrition, 85(2), 426-430
The medication follows a structured dose-escalation schedule over 17 weeks, starting at 0.25 mg and increasing to the 2.4 mg maintenance dose
Every aspect of the treatment process is designed with safety in mind, from initial consultations to follow-up appointments
How GLP-1 Medications Affect Your Body GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1